Locations:
Search IconSearch
October 26, 2018/Opinion

Antidote to rising drug prices languishes in Congress

Media Contact

Cleveland Clinic News Service | 216.444.0141

We’re available to shoot custom interviews & b-roll for media outlets upon request.

Media Downloads

CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.

Multicolored pills on white background.

Cleveland Clinic Chief Pharmacy Officer Scott Knoer, M.S., Pharm.D., writes in The Hill:

Scott Knoer, M.S., Pharm.D., Chief Pharmacy Officer

“Two new proposals from the Trump administration (aimed at lowering drug prices) … should be celebrated. However, neither strategy will halt egregious price increases or bring down overall health care costs bloated by unsustainable drug prices. Prices for the top 20 most-prescribed brands continue to rise at the rate of 12 percent per year or roughly 10 times higher than the average annual rate of inflation.

There’s more to do. The good news is that much of the heavy lifting has already taken place. One simple, effective tool is sitting right in front of Congress and the White House.

It’s called the CREATES Act of 2018. It’s bipartisan. It’s taking aim at drug prices by restoring true competition to the marketplace. And the Congressional Budget Office scored it as a $3.9 billion money-saver.”

Read the entire piece at: Antidote to rising drug prices languishes on the Hill

Latest from the Newsroom

Beri Ridgeway, M.D.

Cleveland Clinic Appoints Beri Ridgeway, M.D., as President of Cleveland Clinic London

Genediting Therapy Shows Success Against Severe Sickle Cell Disease

Gene Editing Therapy Shows Success Against Severe Sickle Cell Disease

Cleveland Clinic's Main Campus lobby

Mandel Foundation Donates $50 Million to Improve Access to Care at Cleveland Clinic

Blood pressure cuff

Experimental Monthly Injectable Reduces a Key Regulator of Blood Pressure

GLP-1 injection pen with a stethoscope

Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease

Hospital Care At Home

Cleveland Clinic Introduces Hospital Care At Home in Ohio

Image of a scaled and tape measure

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

Illustration of digital medical records

AI-Driven Chart Review Accurately Identifies Potential Rare Disease Trial Participants in New Study